Originally Aired: September 27, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
mRNA vaccines are suitable for tackling emerging pandemics due to their rapid development process, superior effectiveness, and favorable safety profile. Therefore, it is anticipated that mRNA will continue to be considered for vaccine development and its therapeutic applications also show promise. However, further maturation of mRNA technologies will be required to be competitive with other modalities in the regular pharmaceutical market. A significant drawback of the currently marketed mRNA products is their low stability requiring storage at negative temperatures, which implies challenges in their transport, and distribution, while consequently increasing costs. Besides the mRNA sequence, the choice of the lipid nanoparticle (LNP) formulation is essential in modulating the shelf-life.
In this GEN webinar, our distinguished guest, Dr. Roland Böttger, will discuss aspects of mRNA stability, focusing on LNP formulation. Moreover, Dr. Böttger will show that the LNP composition is key to enabling advanced stabilization technologies such as dry mRNA presentation for storage at ambient temperatures.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from: